A VSV-EBOV-BASED VACCINE (Vaccine Candidate)
In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
Among these COVID-19 technologies is a vaccine candidate:
A VSV-EBOV-Based Vaccine Against COVID-19:
NIAID researchers, using a rhesus macaque study model, have taken the existing federally approved vaccine against Ebola virus (brand name Ervebo) and modified it to also protect against SARS-CoV-2, the virus that causes COVID-19. Ervebo uses recombinant vesicular stomatitis virus (VSV)—which is typically not harmful to people—to deliver an Ebola virus protein in a vaccine to generate immunity. The same research group that helped develop Ervebo has added an immune-generating protein from SARS-CoV-2 that provided protection in its macaque model. This is one of several examples of how NIAID scientists are testing the safe and cost-effective VSV delivery method in pre-clinical animal models to introduce proteins that generate protection from different viruses.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
| Aim of the licences | To facilitate the manufacture and commercialisation of Covid-19 related health products and vaccines around the world |
| Technology | One licence covers different patents and materials on technologies potentially relevant in the fight against COVID-19. The second licence specifically covers patents on the spike protein. |
| Products | Any product or vaccine that is covered by the Patents or Patent Applications or uses the Licensed Material. |
| Field of use | While one licence on the different technologies is granted for SARS-CoV-2 products for the WHO C-TAP program, the second licence, in relation to spike protein, refers to SARS-CoV-2 vaccines for the WHO C-TAP program. |
| Territory | Worldwide |
| Term | Continuing until the date the last Patent has lapsed, expired, or been invalidated |
| Scope of the grant | Non-exclusive right to grant royalty-bearing sublicences to develop the licensed patents/material into licensed products or vaccines, and to commercialise the licensed products or vaccines |
| Sublicence | MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence |
